- Home
- MOV vs FULC Comparison
MOV vs FULC Comparison
Compare MOV & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOV
- FULC
- Stock Information
- Founded
- MOV 1961
- FULC 2015
- Country
- MOV United States
- FULC United States
- Employees
- MOV N/A
- FULC N/A
- Industry
- MOV Consumer Specialties
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- MOV Consumer Discretionary
- FULC Health Care
- Exchange
- MOV Nasdaq
- FULC Nasdaq
- Market Cap
- MOV 339.1M
- FULC 372.2M
- IPO Year
- MOV 1993
- FULC 2019
- Fundamental
- Price
- MOV $19.77
- FULC $7.00
- Analyst Decision
- MOV Strong Buy
- FULC Buy
- Analyst Count
- MOV 1
- FULC 8
- Target Price
- MOV $31.50
- FULC $7.13
- AVG Volume (30 Days)
- MOV 181.8K
- FULC 407.6K
- Earning Date
- MOV 08-28-2025
- FULC 11-12-2025
- Dividend Yield
- MOV 7.07%
- FULC N/A
- EPS Growth
- MOV N/A
- FULC N/A
- EPS
- MOV 0.77
- FULC N/A
- Revenue
- MOV $655,597,000.00
- FULC N/A
- Revenue This Year
- MOV $0.71
- FULC N/A
- Revenue Next Year
- MOV N/A
- FULC N/A
- P/E Ratio
- MOV $25.67
- FULC N/A
- Revenue Growth
- MOV 0.79
- FULC 2752.05
- 52 Week Low
- MOV $12.85
- FULC $2.32
- 52 Week High
- MOV $22.20
- FULC $8.50
- Technical
- Relative Strength Index (RSI)
- MOV 74.81
- FULC 52.07
- Support Level
- MOV $18.52
- FULC $6.35
- Resistance Level
- MOV $19.91
- FULC $7.87
- Average True Range (ATR)
- MOV 0.54
- FULC 0.39
- MACD
- MOV 0.15
- FULC 0.06
- Stochastic Oscillator
- MOV 95.57
- FULC 42.76
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.